Jeena Sikho Lifecare Limited (JSLL)
Micro CapConsumer stocks · Micro cap · NSE
Jeena Sikho Lifecare Limited (JSLL) is an Indian Ayurveda healthcare provider offering services through 120+ clinics & hospitals and a portfolio of 330+ Ayurveda products. It operates on a capital-light, hub-and-spoke model, focusing on holistic, drug-free wellness and aims to address root causes of illness.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Investable fundamentals, management trust is supportive, price trend argues for patience, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Average · 52/100margin compression · Rev +29% YoY · PAT +29% YoY
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹224 Cr | +28.7% | +3.7% |
| EBITDA | ₹92 Cr | +16.5% | +17.9% |
| Operating margin | 41.0% | -400 bps | +500 bps |
| PAT | ₹66 Cr | +29.4% | +46.7% |
| PAT margin | 29.5% | +15 bps | +863 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Where growth can come from, and what can break the case
FY26 Revenue surged 71% YoY to INR 801.35 Cr, with PAT up 178% YoY. Q4FY26 revenue grew 55% YoY but declined 3% QoQ. Q4 EBITDA margin moderated to 36% from 45% QoQ due to one-off provisions.
While annual growth is robust, the sequential decline in Q4 revenue and significant margin compression due to 'one-off' provisions raise concerns about operational consistency and underlying profitability trends. The capital-light model and expansion are positive, but the impact of these provisions needs closer scrutiny for future quarters.
Revenue by vertical (FY26)
Latest issuer-disclosed distribution across 2 reported categories.
Expanding Service Reach
Expansion pipeline remains robust, with total bed capacity increasing to 2,861 and 2,300 beds currently operational across 120+ clinics & hospitals.
Higher Patient Volumes
IPD volumes grew 65% to 40,454 and OPD volumes grew 69% to ~5.7 lakh patients in FY26, supported by strong patient inflows.
Product Diversification & Reach
Ayurveda Healthcare Products business benefits from product diversification initiatives and expanding customer reach, registering 93% growth in Q4.
Capital-Light Business Model
Low CAPEX per bed (~₹3-4 lakh for 100-bed facility) and a mix of own & franchise assets enable rapid scaling and superior ROCE (46% 3Y average).
Operational Bed Capacity
Total bed capacity increased to 2,861, with 2,300 beds currently operational. Recently added 561 beds.
Beds in Pipeline
445 beds are in the pipeline, expected to enhance capacity and support sustained volume-led growth.
Rising Awareness of Ayurveda
Continued rise in awareness and acceptance of Ayurvedic healthcare solutions across India is strengthening demand visibility.
Government Empanelments
Empanelled for treatment of government employees of Uttar Pradesh, Bihar, Haryana, Punjab, CGHS, CAPF, ECHS, and other entities.
One-off Provisions Impacting Q4 Margins
Sequential moderation in Q4FY26 margins was due to higher provisioning for labour code amendments, ESOP, and performance-linked bonuses (~INR 21 Cr total).
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
YoY comparison is essential to assess the overall growth trajectory and annual performance, especially for a rapidly expanding business. QoQ comparison is crucial to understand sequential momentum, the impact of one-off provisions on Q4 margins, and operational efficiency trends.
Revenue from Operations (FY26)
Revenue from Operations grew 71% YoY for FY26 to INR 80,135 Lakhs.
Profit After Taxes (FY26)
Profit After Taxes grew 178% YoY for FY26 to INR 22,218 Lakhs.
EBITDA Margin (FY26)
For FY26, EBITDA margins improved to 44% compared to 30% in FY25, reflecting operating leverage and scalability.
EBITDA Margin (Q4FY26)
EBITDA margin was 36% in Q4FY26, a sequential moderation from 45% in Q3FY26 due to higher provisioning.
Continued Growth Momentum
Jeena Sikho continued its growth momentum in Q4FY26, delivering strong operational and financial performance across both verticals.
Robust Expansion Pipeline
Our expansion pipeline remains robust, with additions expected to enhance capacity, improve regional penetration, and support sustained volume-led growth.
Focus on Long-Term Value Creation
Efforts like the Jeena Sikho Health Card reinforce our focus on long-term value creation and patient loyalty.
Shareholder Rewards
The Board recommended a final dividend of Rs. 4.50 per equity share for FY26, reflecting confidence and focus on rewarding shareholders.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| EBITDA Margin | 36% (Q4FY26) | Stabilization and recovery of margins in subsequent quarters, confirming the 'one-off' nature of Q4 provisions. |
| Operational Bed Capacity & Utilization | 2,300 operational beds (FY26) | Ramp-up of the 445 beds in pipeline and sustained improvement in occupancy levels across existing facilities. |
| Patient Volumes (IPD & OPD) | 40,454 IPD, 5.7 lakh OPD (FY26) | Continued strong growth in patient inflows, indicating sustained demand and effective market penetration. |
| Jeena Sikho Health Card Rollout | Trial phase with encouraging early response | Successful full-scale rollout and its measurable impact on patient loyalty, referral benefits, and ecosystem integration. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
40NeutralSMA20 -10.5% / mo · MACD + · near 52W low
Technical chart
JSLLdaily · 1Y · AUTO-15.6%Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 46. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~11.7% over last month) — short-term momentum negative.
- RSI(14) at 46 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 67 · UNDERVALUED · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 67 · UNDERVALUED · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
UNDERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 22.4%.
- Quality contributes 20/20 to the score.
Main drags
- Valuation is weaker at 4/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Balance sheet is weaker at 10/15; verify the latest quarterly trend.
Consumer valuation: PE/PEG and brand-quality premium
Consumer franchises can deserve higher multiples, but only when growth quality supports them.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 93rd percentile of the scored universe and 95th percentile within Consumer. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 63.6%. Key concern: OPM spread across recent quarters is 22%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Consumer: 95th pctile, median 66 · Micro: 86th pctile, median 73
34 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 63.6%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.8%.
- ▸ROCE is 64.1%.
Trust risks
- ▸OPM spread across recent quarters is 22%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 27.10
- P/B
- 13.72
- EV/EBITDA
- 15.73
- Market Cap
- 6418.00Cr
Profitability
- ROE
- 61.30%
- ROCE
- 64.10%
- ROA
- 35.01%
- Dividend Y
- 0.87%
Growth (CAGR)
- Revenue 5Y
- 55.11%
- EPS 5Y
- 115.22%
- Revenue 3Y
- 58.00%
- EPS 3Y
- 88.00%
Balance Sheet
- Debt/Equity
- 0.27
- Interest Coverage
- 24.20×
- Altman Z
- 10.08
- Book Value
- 37.60
Cash Flow
- FCF Yield
- 0.81%
- FCF Positive Y
- 2/5
- OCF
- 254.00 Cr
- EPS TTM
- 19.03
Shareholding
- Promoter Hold
- 63.62%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 7%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Consumer, ranked by similarity
Peers
Business-comparable names in Consumer, ranked by similarity
Peers
Business-comparable peers in Consumer — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.